Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Macitentan for CLAD after Lung Transplantation
NCT02893176Phase 4Withdrawn
- Sponsor
- University of California, Los Angeles
- Start
- Sep 2016
- Primary completion
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of macitentan in chronic lung allograft dysfunction (CLAD), sponsored by University of California, Los Angeles. Planned start Sep 2016; status: withdrawn.
02
Drugs
macitentan
03
Conditions
chronic lung allograft dysfunction (CLAD)
Beyond the preview
Go deeper on NCT02893176.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02893176.